作者对97例急性支气管哮喘病人进行双盲试验,研究甲泼尼龙的疗效。所有病人除都接受常规急救治疗外,随机分成2组,分别静脉注射甲泼尼龙125mg或安慰剂。治疗结果,甲泼尼龙组和安慰剂组需要住院者各为19％(9/48)和47％(23/49),两组有显著差异(P<0.003),甲泼尼龙组的主要症状比安慰剂组明显改善。两组病人1周内的复发率无明显不同。甲泼尼龙组病人无毒性反应,无需气管内插管或机械通气,无死亡。研 The authors conducted a double-blind trial of 97 patients with acute bronchial asthma to study the efficacy of methylprednisolone. All patients except for the first aid treatment were randomly assigned to receive intravenous methylprednisolone 125 mg or placebo. In the treatment group, 19% (9/48) and 47% (23/49) of the patients in the methylprednisolone and placebo groups, respectively, had significant differences (P <0.003), the main symptoms of the methylprednisolone group Significant improvement over placebo. There was no significant difference in recurrence rates between the two groups within 1 week. The patients in the methylprednisolone group had no toxic reaction, no endotracheal intubation or mechanical ventilation and no death. research